

**Media Release, March 16, 2012**

## **BB Biotech AG completed its current share buyback program**

On March 15, 2012, BB Biotech AG completed its current share buyback program which was initiated on December 2, 2011. During this period a total of 1 024 150 registered shares were bought back through the second trading line.

### **For further information:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Thomas Egger, Tel. +41 44 267 67 00, [teg@bellevue.ch](mailto:teg@bellevue.ch)

[www.bbbiotech.com](http://www.bbbiotech.com)

### **Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1.2 bn in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.